Over the past decade, improvements in medical treatment and revascularization techniques have been beneficial for patients with peripheral artery disease in the late stage of critical limb ischemia (CLI). We evaluated the putative reduction in the number of major amputees in the Cohorte des Patients ARTeriopathes (COPART) cohort over time. Patients were selected from this multicenter cohort, from 2006 to 2016, for CLI according to Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease II criteria. Patients included before and after 2011 were compared. Patients were followed for 1 year. Primary outcome was the rate of major amputations. Secondary outcomes were minor amputations, deaths from all causes, cardiovascular deaths; 989 patients were included, 489 before 2011 and 450 after 2011. There was a significant decrease in rates of major amputation after 2011 (17% vs 25%), confirmed in multivariate analysis (odds ratio [OR]: 1.5 [1.1-2.2]), an increase in revascularization, particularly distal angioplasty (OR: 2.7 [1.7-4.4]) and increased statin intake (OR: 1.6 [1.1-2.1]). For secondary outcomes, there was no significant difference. Limb prognosis of CLI patients has improved over the past decade, possibly due to more revascularizations, particularly distal ones, and increased statin use.
AboyansVRiccoJ-BBartelinkMEL, et al.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
Baubeta FridhEAnderssonMThuressonM, et al.Amputation Rates, Mortality, and Pre-operative Comorbidities in Patients Revascularised for Intermittent Claudication or Critical Limb Ischaemia: A Population Based Study. Eur J Vasc Endovasc Surg. 2017;54:480–6.
8.
EgorovaNNGuillermeSGelijnsA, et al.An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety. J Vasc Surg. 2010;51:878–85.
9.
ChenSLWhealonMDKabuteyN-KKuoIJSgroiMDFujitaniRM. Outcomes of open and endovascular lower extremity revascularization in active smokers with advanced peripheral arterial disease. J Vasc Surg. 2017;65:1680–9.
10.
FarberAEberhardtRT. The Current State of Critical Limb Ischemia: A Systematic Review. JAMA Surg. 2016;151:1070–77.
11.
CambouJPAboyansVConstansJLacroixPDentansCBuraA. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur J Vasc Endovasc Surg. 2010;39:577–85.
12.
Haute Autorité de Santé. Prise en charge de l’artériopathie chronique oblitérante athéroscléreuse des membres inférieurs (indications médicamenteuses, de revascularisation et de rééducation). Ann Dermatol Vénéréologie. 2007;134:199–206.
13.
MachFBaigentCCatapanoAL, 2019ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J2019, 41, 111–88.
14.
VircoulonMBoulonCDesormaisI, et al.Comparison of one-year prognosis of patients classified as chronic critical lower limb ischaemia according to TASC II or European consensus definition in the COPART cohort. VASA Z Gefasskrankheiten. 2015;44:220–8.
15.
ConstansJBura-RivièreAVisonaA, et al.Urgent need to clarify the definition of chronic critical limb ischemia - a position paper from the European Society for Vascular Medicine. VASA Z Gefasskrankheiten. 2019;48:223–7.
16.
SigvantBKragstermanBFalkenbergM, et al.Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg. 2016; 64:1009–17.
17.
SiracuseJJMenardMTEslamiMH, et al.Comparison of open and endovascular treatment of patients with critical limb ischemia in the Vascular Quality Initiative. J Vasc Surg. 2016; 63:958–65.
18.
Bura RiviereABouéeSLaurendeauCTorretonEGourmelenJThomas-DelecourtF. Outcomes and management costs of peripheral arterial disease in France. J Vasc Surg. 2018; 67:1834–43.
19.
AryaSKhakhariaABinneyZO, et al.Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. Circulation. 2018; 137:1435–46.
20.
SigvantBHasvoldPKragstermanB, et al.Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. J Vasc Surg. 2017; 66:507–514.
21.
HirschATCriquiMHTreat-JacobsonD, et al.Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.
22.
ArmstrongEJChenDCWestinGG, et al.Adherence to Guideline-Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease. J Am Heart Assoc. 2014;3: e000697.
23.
StavroulakisKBorowskiMTorselloGBisdasTCRITISCH collaborators. Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. J Vasc Surg. 2017; 66:1534–42.
24.
WestinGGArmstrongEJBangH, et al.Association Between Statin Medications and Mortality, Major Adverse Cardiovascular Event, and Amputation-Free Survival in Patients With Critical Limb Ischemia. J Am Coll Cardiol. 2014;63:682–90.
25.
KatsikiNTriposkiadisFGiannoukasADMikhailidisDP. Statin loading in cardiovascular surgery: never too early to treat. Curr Opin Cardiol. 2018;33:436–443.
26.
SlhessarenkoJRHirataMSousaA, et al.Effect of Preloading With High Dose of Rosuvastatin on Serum Levels of Inflammatory Markers After Percutaneous Coronary Intervention. J Invasive Cardiol. 2020;32:335–341.
